Q&A

Cold Chain Complexities Of Distributing Temperature-Sensitive Biopharmaceuticals And Cell Therapies

cold chain biopharmaceuticals

A Q&A with Rachel Griffiths, Samantha James, and Rich Nelson, PCI Pharma Services

ABSTRACT

Distributing sensitive biopharmaceuticals and cell therapies is a complex challenge that calls for detailed understanding of the product, access to the latest technologies, and global reach combined with local knowledge.

INTRODUCTION

Pharmaceutical industry interest in biopharmaceuticals, cell therapies and, more recently, biosimilars has increased significantly1,2. In addition to targeting and treating disease more effectively than small molecule medicines, such products have the potential to generate higher revenues and are less likely to face competition when they go off patent3,4.

However, unlike small molecule drugs, which can be easily transported, large molecule biopharmaceuticals are highly sensitive to temperature fluctuations and require special handling5.

VIEW THE Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader